Cyto Wave Technologies

About:

Cyto Wave Technologies offers a technology platform enabling the non-invasive detection and targeted destruction of circulating tumor cells.

Website: http://cytowavetech.com

Description:

Cyto Wave Technologies (“The Company”) has licensed a first-in-class breakthrough technology platform from the University of Arkansas for Medical Sciences (UAMS) that allows the early non-invasive detection, capturing and targeted destruction of metastatic circulating tumor cells (CTCs) in vivo The Company is developing a highly-sensitive, portable device (“iV3″) for real-time detection of CTCs directly in the bloodstream of cancer patients. CTCs are detected by a proprietary laser technology and can then be extracted from the bloodstream. The laser can also potentially destroy CTCs directly. iV3 has been funded with US$4.4 million from the National Health Institutes/National Cancer Institute, the Department of Defense (DoD) and private investors which has alleviated much of the early risk associated with developing a new breakthrough technology. A human clinical trial in melanoma patients is currently being initiated.

Total Funding Amount:

$965000

Headquarters Location:

San Francisco, California, United States

Founded Date:

2012-01-01

Contact Email:

gyu(AT)cytowavetech.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2013-04-04

IPO Status:

Private

Industries:

© 2025 bioDAO.ai